Jennifer Cather

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.

Kim Papp, Jennifer Cather, Craig Leonardi et al. · PubMed · 2016 · 22 citations

Medicine, Dermatology, Pharmacology +12

Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study

Adelaide A. Hebert, Dee Anna Glaser, Lawrence Green et al. · Pediatric Dermatology · 2020 · 21 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +13

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

Lyn Guenther, Richard B. Warren, Jennifer Cather et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 15 citations

Medicine, Dermatology, Pharmacotherapy +8